High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma

BACKGROUND: Renal cell carcinoma (RCC) responds to agents that inhibit vascular endothelial growth factor (VEGF) pathway. Sorafenib, a multikinase inhibitor of VEGF receptor, is effective at producing tumor responses and delaying median progression free survival in patients with cytokine refractory...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Wang, Xiaoen, Zhang, Liang, Goldberg, S Nahum, Bhasin, Manoj, Brown, Victoria, Alsop, David C, Signoretti, Sabina, Mier, James W, Atkins, Michael B, Bhatt, Rupal S
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2011
Témata:
Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3258225/
https://ncbi.nlm.nih.gov/pubmed/22188900
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-9-220
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky